Featured Publications
The Prevalence of Symptomatology and Risk Factors in Mental Health in Mexico: The 2016–17 ENCODAT Cohort
Medina-Mora M, Genis-Mendoza A, Villatoro Velázquez J, Bustos-Gamiño M, Bautista C, Camarena B, Martínez-Magaña J, Nicolini H. The Prevalence of Symptomatology and Risk Factors in Mental Health in Mexico: The 2016–17 ENCODAT Cohort. International Journal Of Environmental Research And Public Health 2023, 20: 3109. PMID: 36833803, PMCID: PMC9961066, DOI: 10.3390/ijerph20043109.Peer-Reviewed Original ResearchConceptsMental healthPost-traumatic stressDrug use disordersMental health disordersSymptoms of maniaMental health symptomsRepresentative population sampleLittle recent informationIllegal drugsRisk factorsTobacco useUse disordersHealth disordersResponse rateHealth symptomsPrevalenceSymptomsInterviews of individualsComorbiditiesDrugsPopulation sampleNational surveySymptomatologyDisordersFinal sample
2023
Profiling neuronal methylome and hydroxymethylome of opioid use disorder in the human orbitofrontal cortex
Rompala G, Nagamatsu S, Martínez-Magaña J, Nuñez-Ríos D, Wang J, Girgenti M, Krystal J, Gelernter J, Hurd Y, Montalvo-Ortiz J. Profiling neuronal methylome and hydroxymethylome of opioid use disorder in the human orbitofrontal cortex. Nature Communications 2023, 14: 4544. PMID: 37507366, PMCID: PMC10382503, DOI: 10.1038/s41467-023-40285-y.Peer-Reviewed Original ResearchConceptsOpioid use disorderMulti-omics findingsGene expression patternsCo-methylation analysisGene expression profilesMulti-omics profilingGene networksDNA methylationNeuronal methylomesDNA hydroxymethylationMethylomic analysisExpression patternsExpression profilesEpigenetic disturbancesUse disordersPsychiatric traitsOrbitofrontal cortexOpioid-related drugsPostmortem orbitofrontal cortexEnvironmental factorsDrug interaction analysisOUD treatmentHuman orbitofrontal cortexOpioid signalingInteraction analysis
2021
Candidate pharmacological treatments for substance use disorder and suicide identified by gene co‐expression network‐based drug repositioning
Cabrera‐Mendoza B, Martínez‐Magaña J, Monroy‐Jaramillo N, Genis‐Mendoza A, Fresno C, Fries GR, Walss‐Bass C, Armenta M, García‐Dolores F, Díaz‐Otañez C, Flores G, Vázquez‐Roque R, Nicolini H. Candidate pharmacological treatments for substance use disorder and suicide identified by gene co‐expression network‐based drug repositioning. American Journal Of Medical Genetics Part B Neuropsychiatric Genetics 2021, 186: 193-206. PMID: 33403748, DOI: 10.1002/ajmg.b.32830.Peer-Reviewed Original ResearchConceptsSubstance use disordersUse disordersBrain gene co-expression networksHub genesPotential pharmacological targetPost-mortem samplesPharmacological treatmentHigh riskCandidate treatmentPharmacological targetsSuicidal behaviorMAOA inhibitorsPrefrontal cortexNonsuicidesDGIdb databaseGene expression profilesPatientsCo-expression networkSuicideDisordersDrugsTreatmentDrug repositioningExpression profilesIndividuals